A Randomized Double Blind Controlled Proof of Concept Study of the Efficacy and Safety of Valcyte® as an Add-on Therapy in Patients With Malignant Glioblastoma With Successful Surgical Resection of at Least 90 % of the Initial Tumor and CMV Infection Demonstrated Histologically and Immunohistochemically.
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Tumor size
week twelve and week twenty four
Inti Peredo, MD
Principal Investigator
Karolinska University Hospital
Sweden: Medical Products Agency
MV20145
NCT00400322
August 2006
March 2009
Name | Location |
---|